Healthcare / BiotechnologySwiss
$0.38
-0.00 (-0.80%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-3.6M · quality 72.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
8/100
SEC 0%
Sin guardar todavía.
Market Cap
$58M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-25.8%
↓Gross Margin
92.1%
↑Debt/Equity
0.05
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2024–2025 · 1 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-1126.2%
FCF / Net income
0.73x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $642000.0 · net income $-9.9M · FCF $-7.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 |
|---|---|---|---|
| Income Statement | |||
| Revenue | $642000.00 | $642000.00 | — |
| Net Income | $-9.9M | $-9.9M | $-1000.00 |
| EBITDA | $-8.0M | $-8.0M | $-1000.00 |
| Gross Margin | 92.1% | 92.1% | — |
| Operating Margin | -1637.9% | -1637.9% | — |
| Net Margin | -1543.0% | -1543.0% | — |
| Balance Sheet | |||
| Debt/Equity | 0.05 | 0.05 | — |
| Cash Flow | |||
| Free Cash Flow | $-7.2M | $-7.2M | $-3000.00 |
| Returns | |||
| ROE | -25.8% | -25.8% | -1.2% |
| Valuation | |||
| P/B | 1.50 | 1.50 | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-64.8%
Start / end P/E
n/dx → n/dx
EPS bridge
n/d → n/d
Residual
-64.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.